Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 2
Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or …
Depressive Disorder, Treatment-ResistantTreatment Resistant Depression (TRD)
Mayo ClinicNCT06668571
Phase 2
A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant the…
Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.NCT07284667
Phase 1
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do …
Depressive Disorder, MajorDepressive Disorder, Treatment-Resistant
Washington University School of MedicineNCT02994433
Phase 2
An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, …
SuicideDepressive Disorder, Treatment-ResistantKetamine+10 more
National Institute of Mental Health (NIMH)NCT06511908